Drugs / Pegylated Interferon (PEG-IFN) alfa-2a
last change Nov 2013 re-read 3 minutes ago

Pegylated Interferon (PEG-IFN) alfa-2a

also known as Peg-IFN alfa-2a · Pegasys · PegIFN

Protein / enzyme biologic

Developed for
hepatitis D virus infection
Investigated by
Hoffmann-La Roche

Trials 1

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT02732639 Oct 2005 → Dec 2008 hepatitis D virus infection Hoffmann-La Roche Completed No outcome recorded
Comparator or background therapy4 trials
Phase 2 NCT00895882 Background Nov 2010 → Jan 2013 chronic hepatitis C virus infection Merck Sharp & Dohme LLC Withdrawn No outcome recorded
Phase 2 NCT00947349 Background Jul 2009 → Aug 2011 chronic hepatitis C virus infection Boehringer Ingelheim Completed No outcome recorded
Phase 2 NCT02716779 Background Apr 2007 → Apr 2010 chronic hepatitis C virus infection Hoffmann-La Roche Completed No outcome recorded
Phase 3 NCT01054573 Background Apr 2010 → Mar 2012 chronic hepatitis C virus infection Janssen Infectious Diseases BVBA Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Pegylated Interferon (PEG-IFN) alfa-2a ClinicalTrials.gov intervention name — accepted as the source's own label NCT02732639 ↗
4

NCT00947349 ↗

NCT01054573 ↗

NCT02716779 ↗

NCT00895882 ↗

Known as Peg-IFN alfa-2a “pegylated interferon (Peg-IFN) alfa-2a” NCT01054573 ↗
Known as Pegasys “Pegylated Interferon Alfa-2a (Pegasys)” NCT01054573 ↗
Known as PegIFN “pegylated interferon (PegIFN) alfa-2a” NCT00947349 ↗
Modality Protein / enzyme biologic “Pegylated Interferon” NCT00895882 ↗
Route Subcutaneous “Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly” NCT00895882 ↗